In 2021, readers were interested in the first mRNA vaccine trial for HIV, an increase in funding for an initiative to end HIV, and more.
Injectable treatments may start to replace daily pills.
New research by shows how one of the major scientific breakthroughs of recent years might be used to eliminate HIV infection.
Johnson & Johnson’s experimental HIV vaccine, which uses the same technology as its COVID-19 vaccine, was found to not be effective at preventing infection.
Biden is proposing a $46 million increase to the Ryan White HIV/AIDS Programs and $20 million for HUD’s Housing Opportunities for Persons with AIDS program. However, no increases were planned for hepatitis programs.
The researchers suggest that additional support may be needed to ensure continuous and potentially increased use of antiretroviral treatment and medication for opioid use disorders and subsequent viral suppression.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
The Growing Popularity of Non-hormonal Menopause Therapy
February 12th 2025Menopausal patients are most interested in learning more about non-hormonal treatments to address their symptoms, according to the results of an international survey led by the Menopause Priority Setting Partnership (MAPS). Monica Christmas, M.D., director of the menopause program at the University of Chicago Medicine and the Center for Women’s Integrated Health, discussed the survey details with Managed Healthcare Executive.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Sarepta Announces Positive Results for Elevidys, Gene Therapy for Duchenne
February 12th 2025Results show improved functional outcomes for people with Duchenne muscular dystrophy who are ambulatory. Elevidys, which is priced at $3.2 million per dose, produced $821 million in net product revenue for the company in 2024.
Read More